Patients with asymptomatic atrial fibrillation are more likely to have a stroke
July 13, 2017 Source: Sina Pharmaceutical News
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Recently, Boehringer Ingelheim announced a new finding in the GLORIA-AF clinical trial that people with symptomatic or asymptomatic non-valvular atrial fibrillation (AF) are more likely to have atrial fibrillation than patients with symptomatic atrial fibrillation A stroke occurred before diagnosis. The reason for this result may be that the diagnosis of asymptomatic atrial fibrillation patients takes longer.
The findings from the global observational study GLORIA?-AF further confirm the need for screening programs.
The data was announced at the EUROPACE CARDIOSTIM 2017 Academic Annual Meeting of the European Society of Cardiology and was included in the selected focus.
Ingelheim, Germany, July 12, 2017 /PRNewswire/ -- Recently, Boehringer Ingelheim announced a new finding in the GLORIA-AF clinical trial, which is rarely symptomatic or asymptomatic compared with patients with symptomatic atrial fibrillation People with non-valvular atrial fibrillation (AF) are more likely to have a stroke before the diagnosis of atrial fibrillation. The reason for this result may be that the diagnosis of asymptomatic atrial fibrillation patients takes longer.
Dr. Steffen Christow, a cardiologist and head of the electrophysiological laboratory at the German hospital Ingolstadt GmbH, believes that “even if there are no symptoms, there is a risk of stroke in patients with atrial fibrillation. Stroke is a serious disease that can lead to disability or even death. GLORIA?- The AF study highlights the need for atrial fibrillation screening programs for high-risk populations, allowing patients with atrial fibrillation to be diagnosed early and receive appropriate anticoagulant therapy and risk factor management to ultimately reduce the risk of atrial fibrillation-related stroke and death."
The global registration program GLORIA?-AF is one of the largest observational studies to collect data on the safety, efficacy and prognosis of long-term anticoagulant drugs in patients with atrial fibrillation in the real world. The subgroup analysis is for 6011 in Western Europe. Patient characteristics of patients with atrial fibrillation were compared. Of these, 4119 patients (69%) had few or no symptoms, and 1892 patients (31%) reported symptoms at the time of diagnosis. These asymptomatic patients had more than twice as many strokes as those with symptomatic atrial fibrillation (14.7% vs. 6.0%).
Professor Joerg Kreuzer, Vice President of Cardiovascular Therapy at Boehringer Ingelheim, said: “GLORIA?-AF is an important study and we are pleased that the above results have been selected for the EHRA focus. We hope that the GLORIA?-AF Institute will Further results will support doctors in their decision to prevent stroke. Future data analysis will include approximately 5,000 patient follow-up data from dabigatran in daily clinical practice worldwide."
Atrial fibrillation is the most common persistent arrhythmia in the world2, and its number is expected to increase in the next few years. Overall, patients diagnosed with atrial fibrillation have a five-fold increased risk of stroke (the stroke occurs when the blood vessels in the brain are blocked by blood clots). 3 Three million patients have atrial fibrillation-related stroke each year.
Anticoagulant treatment options include vitamin K antagonists such as warfarin (VKA) and new non-vitamin K oral anticoagulants (NOAC) such as dabigatran. Boehringer Ingelheim is full of Tai Bi? Dabigatran etexilate, marketed as a trade name, is the first non-vitamin K oral anticoagulant approved for stroke prevention in patients with atrial fibrillation, representing a major advance in the field of anticoagulant therapy. Tai Biquan? It is currently the only non-vitamin K oral anticoagulant with the approved reversal agent Praxbind® (Idafexumab) and is widely used in many countries around the world.
Note: Praxbind? (Edaserizumab) has not been approved in mainland China.
Black Garlic,Fermented Black Garlic,Black Garlic Puree,Natural Fermented Black Garlic Powder
shandong changrong international trade co.,ltd. , https://www.changronggarliccn.com